Targeted therapy is a very widely used drug that has come to market in the last decade or so. Patients with genetic mutations can use targeted drugs, but with different changes. The time to develop resistance to targeted drugs for lung cancer is divided into the following cases: 1. EGFR gene mutation, which accounts for a relatively large population, most of them develop resistance in 8-14 months, after which further testing is needed before replacing new targeted drugs or replacing them with local therapy on top of the original one, depending on the patient’s current progress, whether it is slow progression, local progression, or rapid progression. If it is rapid progression, it is likely that further testing will need to be done on the basis and then chemotherapy. 2, other aspects of genetic mutations, such as ALK gene mutation, ALK gene mutation is a golden mutation, because the survival time is longer, crizotinib appears resistant in about 11 months, while aletinib will be longer, but the drug use time is shorter. Clinical studies as well as clinical applications are not very long, so the perception of drug resistance is now less clear than with EGFR-targeted therapeutics.